- Home
- ICAD vs CHRS Comparison
ICAD vs CHRS Comparison
Compare ICAD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICAD
- CHRS
- Stock Information
- Founded
- ICAD 1984
- CHRS 2010
- Country
- ICAD United States
- CHRS United States
- Employees
- ICAD N/A
- CHRS N/A
- Industry
- ICAD Medical/Dental Instruments
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICAD Health Care
- CHRS Health Care
- Exchange
- ICAD Nasdaq
- CHRS Nasdaq
- Market Cap
- ICAD 103.3M
- CHRS 84.2M
- IPO Year
- ICAD 1986
- CHRS 2014
- Fundamental
- Price
- ICAD $3.81
- CHRS $0.95
- Analyst Decision
- ICAD Hold
- CHRS Buy
- Analyst Count
- ICAD 1
- CHRS 3
- Target Price
- ICAD N/A
- CHRS $4.68
- AVG Volume (30 Days)
- ICAD 171.1K
- CHRS 1.3M
- Earning Date
- ICAD 08-12-2025
- CHRS 08-07-2025
- Dividend Yield
- ICAD N/A
- CHRS N/A
- EPS Growth
- ICAD N/A
- CHRS N/A
- EPS
- ICAD N/A
- CHRS N/A
- Revenue
- ICAD $19,528,000.00
- CHRS $272,251,000.00
- Revenue This Year
- ICAD $3.60
- CHRS N/A
- Revenue Next Year
- ICAD N/A
- CHRS $99.43
- P/E Ratio
- ICAD N/A
- CHRS N/A
- Revenue Growth
- ICAD 8.86
- CHRS 19.87
- 52 Week Low
- ICAD $1.19
- CHRS $0.66
- 52 Week High
- ICAD $4.02
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- ICAD 57.70
- CHRS 59.04
- Support Level
- ICAD $3.68
- CHRS $0.73
- Resistance Level
- ICAD $3.86
- CHRS $0.82
- Average True Range (ATR)
- ICAD 0.14
- CHRS 0.04
- MACD
- ICAD -0.00
- CHRS 0.02
- Stochastic Oscillator
- ICAD 83.80
- CHRS 88.02
About ICAD iCAD Inc.
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment includes image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.